Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.

被引：0
|
作者：
Kosmin, Michael
Makris, Andreas
Sokhi, Heminder
Thijssen, Toon
Padhani, Anwar R.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Acad Oncol Unit, Pinner, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Paul Strickland Scanner Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12544
引用
收藏
页数：6
相关论文
共 50 条
  • [41] PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
    Degeling, K.
    Wong, H. L.
    Johns, J.
    Koffijberg, H.
    Gibbs, P.
    IJzerman, M.
    VALUE IN HEALTH, 2019, 22 : S96 - S96
  • [42] Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
    Eleazar Omar Macedo-Pérez
    Vicente Morales-Oyarvide
    Víctor Osvaldo Mendoza-García
    Yuzmiren Dorantes-Gallareta
    Diana Flores-Estrada
    Oscar Arrieta
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 681 - 690
  • [43] Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
    Omar Macedo-Perez, Eleazar
    Morales-Oyarvide, Vicente
    Osvaldo Mendoza-Garcia, Victor
    Dorantes-Gallareta, Yuzmiren
    Flores-Estrada, Diana
    Arrieta, Oscar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 681 - 690
  • [44] Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.
    Gulhati, Pat
    Yin, Jun
    Pederson, Levi
    Schmoll, Hans-Joachim
    Hoff, Paulo Marcelo
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Tournigand, Christophe
    Tebbut, Niall
    Chibaudel, Benoist
    De Gramont, Aimery
    Shi, Qian
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
    Fitzgerald, Kelly N.
    Duzgol, Cihan
    Knezevic, Andrea
    Shapnik, Natalie
    Kotecha, Ritesh
    Aggen, David H.
    Carlo, Maria I.
    Shah, Neil J.
    Voss, Martin H.
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung -Han
    EUROPEAN UROLOGY, 2023, 83 (03) : 195 - 199
  • [46] Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma
    Ghali, Helana
    Dugan, Michelle M.
    Aflatooni, Shaliz
    Boby, Aleena
    Depalo, Danielle K.
    Laborde, Jose
    Choi, Junsung
    Ahmed, Altan F.
    Zager, Jonathan S.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) : 9150 - 9158
  • [47] Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
    Courtinard, Coralie
    Gourgou, Sophie
    Jacot, William
    Carton, Matthieu
    Guerin, Olivier
    Vacher, Laure
    Bertaut, Aurelie
    Le Deley, Marie-Cecile
    Perol, David
    Marino, Patricia
    Levy, Christelle
    Uwer, Lionel
    Perrocheau, Genevieve
    Schiappa, Renaud
    Bachelot, Florence
    Parent, Damien
    Breton, Mathias
    Petit, Thierry
    Filleron, Thomas
    Loeb, Agnes
    Pelissier, Simone Mathoulin
    Robain, Mathieu
    Delaloge, Suzette
    Bellera, Carine
    BMC MEDICINE, 2023, 21 (01)
  • [48] Progression-free survival is a surrogate of survival in maintenance therapy for metastatic breast cancer: Randomized trial level analysis
    Song, E.
    Yao, H.
    Yu, Y.
    Ou, Q.
    Wang, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Real world progression-free survival in patients with advanced or metastatic urothelial cancer treated with first-line platinum-based chemotherapy
    Nikolaidis, Christos
    Li, Chen
    Lee, Chooi
    Mecke, Almut
    Reyes-Rivera, Irmarie
    Schroder, Carsten
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 319 - 319
  • [50] Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
    Montagnani, Francesco
    Migali, Cristina
    Fiorentini, Giammaria
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : E132 - E133
12345